DOFETILIDE PACKAGE INSERT PDF
Dofetilide (Tikosyn) Considerations for Use*. US/FDA Special Notes. The patient must be registered to receive this drug; the hospital and pharmacy must. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Tikosyn (Dofetilide). (dofetilide) product monograph and refers you to more detailed information in read the patient package insert and reread it each time therapy is renewed in.
|Published (Last):||8 November 2016|
|PDF File Size:||8.79 Mb|
|ePub File Size:||20.63 Mb|
|Price:||Free* [*Free Regsitration Required]|
Emtricitabine; Tenofovir disoproxil fumarate: Dofetilids to the manufacturer, propafenone antiarrhythmic agents is associated with QT prolongation and ventricular arrhythmias and concurrent exposure with dofetilide could increase the risk of dofetilide-induced proarrhythmias. Lamotrigine is an inhibitor of renal tubular secretion via organic cationic transporter 2 OCT2 proteins, and dofetilide doeftilide excreted via this route.
Patients with sick sinus syndrome or with 2nd or 3rd degree AV block were not included in Phase III clinical trials unless a functioning pacemaker were present. Clinically relevant QT prolongation may occur with deutetrabenazine.
Limited data are available regarding the safety of maprotiline in combination with other QT-prolonging drugs. Severe Because of the potential for torsade de pointes TdPuse of toremifene with dofetilide is contraindicated.
Chlorpromazine is specifically associated with an established risk of QT prolongation and TdP; case reports have included patients receiving therapeutic doses of chlorpromazine.
Glasdegib therapy may result in QT prolongation and ventricular arrhythmias including ventricular fibrillation and ventricular tachycardia. Dofetilide did not influence cardiac conduction velocity and sinus node function in a variety of studies in patients with or without structural heart disease. Severe Some quinolones, including ofloxacin, have been associated with QT prolongation and infrequent cases of arrhythmia. Severe Paxkage of the potential for torsade de vofetilide TdPuse of gemifloxacin with dofetilide is contraindicated.
Severe Because of the potential for torsade de pointes TdPuse of histrelin with dofetilide is contraindicated. Androgen deprivation therapy e. Before administering inaert, discontinue use of dofetilide and allow a sufficient washout period to pass.
Increases in QTc interval have been observed in healthy volunteers treated with sparfloxacin, and torsade de pointes has been knsert in patients receiving sparfloxacin with disopyramide and amiodarone. If co-use is advised, patients should receive periodic blood pressure and heart rate monitoring. There are no quantifiable metabolites circulating in plasma, but five metabolites have been identified in the urine.
Because of the potential for TdP, use of dofetilide with methadone is contraindicated. Palbociclib is a weak time-dependent CYP3A4 inhibitor.
If a breast-feeding infant experiences an adverse effect related inaert a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA. Dofetilide is not effective in patients with paroxysmal atrial fibrillation. Hawthorn thus has effects similar to the class III antiarrhythmics and would theoretically interact with drugs with similar cardiac electrophysiology e.
According to the manufacturer, Class I disopyramide, encainide, flecainide, lidocaine, mexiletine, moricizine, procainamide, propafenone, quinidine, and tocainide antiarrhythmic agents are associated with QT prolongation and ventricular arrhythmias and concurrent exposure with dofetilide could increase the risk of dofetilide-induced proarrhythmias.
QT prolongation should be expected with the administration of arsenic trioxide. Females, elderly patients, patients with diabetes mellitus, thyroid disease, malnutrition, alcoholism, or hepatic dysfunction may also be at increased risk for QT prolongation.
Tamoxifen has been reported to prolong the QT interval, usually in overdose or when used in high doses. Severe Potential QT prolongation has been reported in limited case reports with metronidazole. During clinical trials of dofetilide, potassium concentrations were generally maintained between 3. Major Dofetilide should be co-administered with tenofovir alafenamide with caution since both drugs are actively secreted via cationic secretion and could compete for common renal iinsert transport systems.
There was a problem providing the content you requested
Because of the potential for torsades de pointes TdPuse of dofetilide with eribulin is contraindicated. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner.
Because of the potential for torsade pointes TdPuse of dofetilide with degarelix is contraindicated. Iloperidone has been associated with QT prolongation; however, TdP has not been reported. Delavirdine may theoretically inhibit the CYP3A4 metabolism of dofetilide, resulting in elevated dofetilide plasma concentrations.
The use of dofetilide in conjunction with other drugs that prolong the QT interval has dofetiliee been studied and is generally not recommended due to the potential risk for ventricular tachycardia, including TdP and monomorphic packagd tachycardia.